Last reviewed · How we verify
R-pola-mini-CHP
R-pola-mini-CHP is a mini-chemotherapy regimen combining rituximab with a reduced-intensity chemotherapy backbone (mini-CHP) designed to treat lymphoma with lower toxicity.
R-pola-mini-CHP is a mini-chemotherapy regimen combining rituximab with a reduced-intensity chemotherapy backbone (mini-CHP) designed to treat lymphoma with lower toxicity. Used for Diffuse large B-cell lymphoma (DLBCL) in elderly or frail patients.
At a glance
| Generic name | R-pola-mini-CHP |
|---|---|
| Sponsor | Nordic Lymphoma Group |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen pairs rituximab, a CD20-targeting monoclonal antibody, with a mini-chemotherapy combination (mini-CHP: cyclophosphamide, doxorubicin, and prednisone at reduced doses) to achieve anti-lymphoma efficacy while minimizing cumulative toxicity. The rituximab component provides targeted B-cell depletion, while the reduced-dose chemotherapy provides additional cytotoxic activity, making it suitable for elderly or frail patients with lymphoma.
Approved indications
- Diffuse large B-cell lymphoma (DLBCL) in elderly or frail patients
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea/vomiting
- Cardiotoxicity
Key clinical trials
- A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP (PHASE2)
- A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
- A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-pola-mini-CHP CI brief — competitive landscape report
- R-pola-mini-CHP updates RSS · CI watch RSS
- Nordic Lymphoma Group portfolio CI